Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. November 2017 16:30 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conference

ALPHARETTA, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
13. November 2017 07:30 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting

ALPHARETTA, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
08. November 2017 07:00 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
01. November 2017 08:30 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. to Report Third Quarter 2017 Financial Results on November 8, 2017 – Conference Call to Follow

ALPHARETTA, Ga., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug...
24. Oktober 2017 16:30 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

ALPHARETTA, Ga., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
09. August 2017 07:00 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. Announces Second Quarter 2017 Financial Results and Provides Corporate Update

ALPHARETTA, Ga., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
08. August 2017 16:05 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. Announces Participation in Upcoming Events

ALPHARETTA, Ga., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
08. August 2017 08:00 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. Announces Changes to its Board of Directors

ALPHARETTA, Ga., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
07. August 2017 08:00 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical Announces Completion of Patient Enrollment in Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA for Suprachoroidal Administration in Patients with Macular Edema Associated with Non-Infectious Uveitis

ALPHARETTA, Ga., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
02. August 2017 08:00 ET | Quelle: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. to Report Second Quarter 2017 Financial Results on August 9, 2017 – Conference Call to Follow

ALPHARETTA, Ga., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) (“Clearside” or the “Company”), a late-stage biopharmaceutical company developing first-in-class drug...

Vorherige Seite